Omnicell (NASDAQ: OMCL) reported Q3 EPS of $0.60, $0.11 better than the analyst estimate of $0.49. Revenue for the quarter came in at $213.7 million versus the consensus estimate of $208.46 million.

“We are pleased with the solid financial performance this quarter, which exceeded the high end of our guidance ranges,” said Randall Lipps, chairman, president, chief executive officer, and founder of Omnicell. “We continued to increase new customer wins and bookings, particularly with the top 300 U.S. health systems, as our customers embrace the vision of the autonomous pharmacy. We believe this renewed momentum underscores the critical importance of Omnicell’s solutions, and we remain confident we are well-positioned to continue executing on our strategy and drive significant long-term value for shareholders, healthcare partners, and patients.”

GUIDANCE:

Omnicell sees Q4 2020 EPS of $0.72-$0.77, versus the consensus of $0.72. Omnicell sees Q4 2020 revenue of $238-244 million, versus the consensus of $236.4 million.

Omnicell sees FY2020 EPS of $2.35-$2.40, versus the consensus of $2.24. Omnicell sees FY2020 revenue of $865-900 million, versus the consensus of $874.11 million.

For earnings history and earnings-related data on Omnicell (OMCL) click here.